Middle East Healthcare Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Middle East Healthcare is de winst gegroeid met een gemiddeld jaarlijks percentage van 20.8%, terwijl de Healthcare industrie de winst jaarlijks groeide met 20.3%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 13.8% per jaar. Het rendement op eigen vermogen van Middle East Healthcare is 12.4%, en het heeft een nettomarge van 7.4%.
Belangrijke informatie
20.8%
Groei van de winst
20.8%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 12.3% |
| Inkomstengroei | 13.8% |
| Rendement op eigen vermogen | 12.4% |
| Nettomarge | 7.4% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Investors Will Want Middle East Healthcare's (TADAWUL:4009) Growth In ROCE To Persist
Sep 24
Middle East Healthcare Company (TADAWUL:4009) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 09Middle East Healthcare Company's (TADAWUL:4009) Price In Tune With Earnings
Jul 18There's Been No Shortage Of Growth Recently For Middle East Healthcare's (TADAWUL:4009) Returns On Capital
May 30Middle East Healthcare Company Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 09If EPS Growth Is Important To You, Middle East Healthcare (TADAWUL:4009) Presents An Opportunity
Apr 29Why Investors Shouldn't Be Surprised By Middle East Healthcare Company's (TADAWUL:4009) 27% Share Price Plunge
Apr 02There's Reason For Concern Over Middle East Healthcare Company's (TADAWUL:4009) Massive 40% Price Jump
Feb 11Returns On Capital At Middle East Healthcare (TADAWUL:4009) Have Stalled
Feb 08Should You Be Adding Middle East Healthcare (TADAWUL:4009) To Your Watchlist Today?
Jan 18Middle East Healthcare Company's (TADAWUL:4009) Revenues Are Not Doing Enough For Some Investors
Dec 28Middle East Healthcare (TADAWUL:4009) Will Want To Turn Around Its Return Trends
Sep 26Some Investors May Be Worried About Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Jun 28Investors Could Be Concerned With Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Mar 30Capital Allocation Trends At Middle East Healthcare (TADAWUL:4009) Aren't Ideal
Sep 20Calculating The Intrinsic Value Of Middle East Healthcare Company (TADAWUL:4009)
Jun 14Returns On Capital At Middle East Healthcare (TADAWUL:4009) Paint A Concerning Picture
Apr 18Here's What's Concerning About Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Aug 10Middle East Healthcare (TADAWUL:4009) Will Will Want To Turn Around Its Return Trends
Mar 29An Intrinsic Calculation For Middle East Healthcare Company (TADAWUL:4009) Suggests It's 28% Undervalued
Mar 03Are Middle East Healthcare's (TADAWUL:4009) Statutory Earnings A Good Guide To Its Underlying Profitability?
Feb 10Weak Financial Prospects Seem To Be Dragging Down Middle East Healthcare Company (TADAWUL:4009) Stock
Jan 23If You Had Bought Middle East Healthcare's (TADAWUL:4009) Shares Three Years Ago You Would Be Down 38%
Jan 05Should You Be Impressed By Middle East Healthcare's (TADAWUL:4009) Returns on Capital?
Dec 18Calculating The Fair Value Of Middle East Healthcare Company (TADAWUL:4009)
Nov 30Opbrengsten en kosten
Hoe Middle East Healthcare geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 2,854 | 211 | 512 | 0 |
| 30 Jun 24 | 2,793 | 203 | 668 | 0 |
| 31 Mar 24 | 2,704 | 182 | 654 | 0 |
| 31 Dec 23 | 2,653 | 180 | 661 | 0 |
| 30 Sep 23 | 2,551 | 177 | 603 | 0 |
| 30 Jun 23 | 2,393 | 135 | 574 | 0 |
| 31 Mar 23 | 2,276 | 105 | 551 | 0 |
| 31 Dec 22 | 2,152 | 75 | 532 | 0 |
| 30 Sep 22 | 2,033 | 24 | 547 | 0 |
| 30 Jun 22 | 2,019 | 27 | 569 | 0 |
| 31 Mar 22 | 1,968 | 26 | 565 | 0 |
| 31 Dec 21 | 1,873 | 17 | 541 | 0 |
| 30 Sep 21 | 1,823 | 45 | 493 | 0 |
| 30 Jun 21 | 1,816 | 66 | 474 | 0 |
| 31 Mar 21 | 1,733 | 73 | 438 | 0 |
| 31 Dec 20 | 1,751 | 82 | 454 | 0 |
| 30 Sep 20 | 1,708 | 110 | 443 | 0 |
| 30 Jun 20 | 1,603 | 108 | 400 | 0 |
| 31 Mar 20 | 1,583 | 104 | 399 | 0 |
| 31 Dec 19 | 1,497 | 98 | 360 | 0 |
| 30 Sep 19 | 1,401 | 91 | 341 | 0 |
| 30 Jun 19 | 1,353 | 78 | 344 | 0 |
| 31 Mar 19 | 1,346 | 100 | 335 | 0 |
| 31 Dec 18 | 1,391 | 172 | 326 | 0 |
| 30 Sep 18 | 1,445 | 224 | 317 | 0 |
| 30 Jun 18 | 1,459 | 269 | 304 | 0 |
| 31 Mar 18 | 1,464 | 297 | 300 | 0 |
| 31 Dec 17 | 1,462 | 319 | 297 | 0 |
| 30 Sep 17 | 1,503 | 322 | 342 | 0 |
| 30 Jun 17 | 1,529 | 356 | 372 | 0 |
| 31 Mar 17 | 1,588 | 368 | 426 | 0 |
| 31 Dec 16 | 1,616 | 363 | 466 | 0 |
| 30 Sep 16 | 1,629 | 380 | 462 | 0 |
| 30 Jun 16 | 1,602 | 371 | 448 | 0 |
| 31 Mar 16 | 1,564 | 389 | 425 | 0 |
| 31 Dec 15 | 1,535 | 390 | 418 | 0 |
| 30 Sep 15 | 1,485 | 373 | 413 | 0 |
| 30 Jun 15 | 1,456 | 356 | 424 | 0 |
| 31 Mar 15 | 1,431 | 357 | 405 | 0 |
| 31 Dec 14 | 1,399 | 332 | 424 | 0 |
| 31 Dec 13 | 828 | 137 | 285 | 0 |
Kwaliteitswinsten: 4009 heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (7.4%) 4009 } zijn hoger dan vorig jaar (6.9%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van 4009 is de afgelopen 5 jaar aanzienlijk gegroeid met 20.8% per jaar.
Versnelling van de groei: De winstgroei van 4009 over het afgelopen jaar ( 19.5% ) ligt onder het 5-jarig gemiddelde ( 20.8% per jaar).
Winst versus industrie: De winstgroei 4009 over het afgelopen jaar ( 19.5% ) overtrof de Healthcare -sector 13.5%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 12.4% ) van 4009 wordt als laag beschouwd.